Ticagrelor is a member of the chemical class cyclopentyltriazolopyrimidines (CPTP). It is a selective adenosine diphosphate (ADP) receptor antagonist acting on the P2Y12 ADP-receptor that can prevent ADP-mediated platelet activation and aggregation. Ticagrelor reversibly interacts with the platelet P2Y12 ADP-receptor. Ticagrelor does not interact with the ADP binding site itself, but interacts with platelet P2Y12 ADP-receptor to prevent signal transduction. Thus it prevents platelet activation & aggregation.
Each film coated tablet contains Ticagrelor INN 90 mg.
Ticacard is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Ticacard treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily. Patients taking Ticacard should also take aspirin daily, unless specifically contraindicated. Following an initial dose of aspirin (usually 325 mg), Ticacard should be used with a maintenance dose of aspirin of 75-100 mg. Maintenance dose of aspirin above 100 mg decreased the efficacy of Ticacard. So, maintenance dose of aspirin above 100 mg should be avoided. A patient who misses a dose of Ticacard should take only one 90 mg tablet (their next dose) at its scheduled time. Patients treated with clopidogrel can be directly switched to Ticacard if needed. Switching from prasugrel to ticagrelor has not been investigated. Treatment is recommended for up to 12 months unless discontinuation of Ticacard is clinically indicated. Ticacard can be administered with or without food.
Ticagrelor is contraindicated in case of any hypersensitivity to ticagrelor or to any of the excipients, active pathological bleeding (peptic ulcer),history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).
Bleeding (major & minor), dyspnea, headache, cough, dizziness, nausea, atrial fibrillation, hypertension, diarrhea, back pain, hypotension, fatigue, chest pain.
CYP3A inhibitors: Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin). CYP3A inducers: Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin, carbamazepine and phenobarbital). Aspirin:Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness of Ticagrelor. Simvastatin, lovastatin: Ticagrelor will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg. Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in ticagrelor therapy. Other Concomitant Therapy: Ticagrelor can be administered with unfractionated or low-molecular-weight heparin, GPIIb/IIIa inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.
Pregnancy: Pregnancy category C. There are no or limited amount of data from the use of ticagrelor in pregnant women. Ticagrelor is not recommended during pregnancy.
Nursing mothers: Available pharmacodynamic/toxicological data in animals have shown excretion of ticagrelor and its active metabolites in milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Paediatric Use: The safety and efficacy of ticagrelor in children below the age of 18 in the approved adult indication has not been established.
Elderly: No dose adjustment is required in elderly.
Renal impaired patients: No dose adjustment is necessary for patients with renal impairment. Ticagrelor is not recommended for renal dialysis.
Hepatic impaired patients: Its use in moderate to severe hepatic impairment is contradicated. No dose adjustment is required for patients with mild hepatic impairment.
Ticacard: Each box contains 10 tablets in alu-alu blister packs.
FR
DE
